No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 321,966 | 301,961 | 361,730 | 388,614 | 382,279 | 420,647 | 411,966 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 20,201 | 27,716 | 33,413 | 10,569 | 31,101 | 26,199 | 36,225 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Zeon Corporation, based in Tokyo, Japan, and established in 1950, operates across diverse sectors including elastomers, specialized materials, and various other ventures. Its elastomers segment encompasses the production of synthetic rubbers, including general-purpose types utilized in automotive tires, alongside specialized rubbers such as NBR and hydrogenated NBR. The company also supplies synthetic latex varieties like styrene-butadiene copolymer latex, polybutadiene, and acrylonitrile butadiene copolymer latex, which find application in areas such as paper processing, fiber treatment, adhesives, paints, and rubber gloves. Furthermore, it produces materials for adhesive tapes, hot melt adhesives, binders for road marking paints, and additives for concrete. In specialty chemicals, Zeon provides synthetic aromatic compounds for the flavor and fragrance industries, as well as cyclopentene, cyclopentanone, and their derivatives for chemical synthesis. They also offer intermediates crucial for pharmaceuticals and agrochemicals, alongside solvents and cleaning agents. For the electronics industry, the firm offers electronic materials, components for rechargeable batteries, and toners, all essential for manufacturing semiconductors, etching gases, and battery production. Its specialty plastics range includes cyclo olefin polymers (COP) and sophisticated products derived from COP, which are employed in optical lenses, medical apparatus, and a variety of common engineering plastics. Beyond materials, Zeon is involved in the development, manufacturing, and sales of medical devices for cardiovascular and gastrointestinal health, in addition to nutritional supplements. The company also engages in technology transfer, licensing its butadiene recovery and butene purification processes to around 23 countries globally. A notable product offering is PENTAM, an energy- and resource-efficient molded item.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Zeon Corporation, based in Tokyo, Japan, and established in 1950, operates across diverse sectors including elastomers, specialized materials, and various other ventures. Its elastomers segment encompasses the production of synthetic rubbers, including general-purpose types utilized in automotive tires, alongside specialized rubbers such as NBR and hydrogenated NBR. The company also supplies synthetic latex varieties like styrene-butadiene copolymer latex, polybutadiene, and acrylonitrile butadiene copolymer latex, which find application in areas such as paper processing, fiber treatment, adhesives, paints, and rubber gloves. Furthermore, it produces materials for adhesive tapes, hot melt adhesives, binders for road marking paints, and additives for concrete. In specialty chemicals, Zeon provides synthetic aromatic compounds for the flavor and fragrance industries, as well as cyclopentene, cyclopentanone, and their derivatives for chemical synthesis. They also offer intermediates crucial for pharmaceuticals and agrochemicals, alongside solvents and cleaning agents. For the electronics industry, the firm offers electronic materials, components for rechargeable batteries, and toners, all essential for manufacturing semiconductors, etching gases, and battery production. Its specialty plastics range includes cyclo olefin polymers (COP) and sophisticated products derived from COP, which are employed in optical lenses, medical apparatus, and a variety of common engineering plastics. Beyond materials, Zeon is involved in the development, manufacturing, and sales of medical devices for cardiovascular and gastrointestinal health, in addition to nutritional supplements. The company also engages in technology transfer, licensing its butadiene recovery and butene purification processes to around 23 countries globally. A notable product offering is PENTAM, an energy- and resource-efficient molded item.
